DCTHDelcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphala…
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. | ||
 Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out. | ||
 Does Delcath Systems (DCTH) Have the Potential to Rally 42.77% as Wall Street Analysts Expect? The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. | ||
 These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months Delcath Systems announced a return to profitability after posting losses in the past two quarters, while Praxis’ second-quarter loss came in narrower than Wall Street had expected | ||
 Delcath Systems Q2 Earnings Call Highlights Delcath Systems (NASDAQ:DCTH) reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier, as growth in HEPZATO KIT sales supported continued commercial expansion and investment in clinical programs beyond metastatic uveal melanoma. HEPZATO KIT revenue totaled $27.1 | ||
 Delcath Systems, Inc. (DCTH) Tops Q2 Earnings and Revenue Estimates Delcath Systems (DCTH) delivered earnings and revenue surprises of +143.75% and +15.88%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates Orthofix (OFIX) delivered earnings and revenue surprises of +333.33% and +0.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates Idexx (IDXX) delivered earnings and revenue surprises of +8.10% and +1.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Delcath (DCTH) Q1 2026 Earnings Transcript David Hoffman: Thank you, and welcome to Delcath Systems First Quarter 2026 Earnings Call. With me on the call are Gerard Michel, Chief Executive Officer; Sandra Pennell, Chief Financial Officer; Kevin Muir, Chief Commercial Officer; Vojislav Vukovic, Chief Medical Officer; and Martha Rook, Chief Operating Officer. | ||
 Delcath Systems, Inc. Q1 2026 Earnings Call Summary Moby summary of Delcath Systems, Inc.'s Q1 2026 earnings call | ||